Join ScienceWebinars for their next free, educational broadcast on 12 October at 12 noon ET ➡️ Predicting through multiplexing: Immune checkpoint inhibition benefits in advanced NSCLC. Submit your questions for the panel: Webinar
The dynamics of tumor and immune responses associated with immune checkpoint blockade are unique and complex. Despite the initial successes of immunotherapy, a low objective response rate due to resistance is still the main challenge in solid tumors, particularly advanced-stage lung cancer. One manifestation of tumor-immune dynamics is a release of soluble immune checkpoints and regulators to the surrounding microenvironment and circulation, the biological role of which has yet to be revealed.
A holistic snapshot of circulating immune checkpoints and regulators along the course of cancer progression can provide insights into the crosstalk between the immune system and a progressing tumor. Simultaneously capturing those circulating molecules can also establish tumor behavior predictions in response to immune checkpoint inhibitors.
Join this webinar to learn how research evaluating multiple soluble immune checkpoints in serum may help identify those likely to benefit from PD-1/PD-L1 immunotherapy and may reveal new immunotherapy targets for future investigation.Learn why analyzing multiple circulating immune checkpoint molecules is critical to understanding tumor progressionGain insights into the advantages of using a large multiplex immunoassay to test research samples*For Research Use Only.